Genomic testing can identify biomarkers to target specific types of cancers and help prevent normal cells from being harmed by therapy and reduce side effects. Knowing which biomarkers are driving a patient’s tumor growth could open the door to personalized treatment options, including access to clinical trials that may give patients the chance to live well and longer.
Genetic vs genomic testing – what’s the difference? Genetic testing is done using a sample of blood, urine, saliva, hair, amniotic or other body fluid, to test for inherited mutations from your parents that could increase your risk for certain types of cancer. Genomic testing checks your tumor cells for biomarkers to help form a treatment plan.Identifying molecular and genetic testing is critical for matching patients up with new therapies being developed. We need to understand them and make sure our AC/PMP patients are being tested for them. If you have been diagnosed with cancer, talk to your oncologist about genomic testing.
Join the zebra herd and spread the word about rare cancers and genomic testing this #RareCancerDay (September 30th)!
(833) 227-6773
info@acpmp.org
751 Sproul Road #1057, Springfield, PA 19064
Rare Cancer Day is an annual awareness day devoted to shining a light on rare cancers and the issues people living with them face. Spearheaded by the NORD Rare Cancer Coalition, which is composed of 27 rare cancer-specific member organizations, including the ACPMP Research Foundation. Rare Cancer Day is observed on September 30, 2020 to highlight the challenges patients face and to unify individuals living with rare cancers for awareness and early diagnosis.